The US Food and Drug Administration (FDA) has granted final approval to Breckenridge Pharmaceutical Inc, a subsidiary of Laboratorios Pen, SA, for its Abbreviated New Drug Application (ANDA) for Asenapine Sublingual Tablets in 2.5mg and 10mg strengths (generic for Saphris), it was reported on Friday.
Breckenridge Pharmaceutical is planning to introduce these strengths immediately.
The FDA has granted tentative approval for the 5mg strength. The product was developed in partnership with MSN Laboratories Private Limited. The product is intended for the treatment of mental/mood disorders.
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Avera joins Civica to help maintain drug supplies
Apotex launches generic version of Tasigna in US market
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets